Hypofractionated and single-fraction radiosurgery for brain metastases with sex as a key predictor of overall survival

Author:

Mangesius Julian1ORCID,Thomas Seppi2,Katie Bates1,Arnold Christoph ReinholdORCID,Danijela Minasch1,Stephanie Mangesius1,Johannes Kerschbaumer1,Peter Lukas1,Ute Ganswindt1,Meinhard Nevinny-Stickel1

Affiliation:

1. Medical University of Innsbruck

2. Medical University of Innsrbuck

Abstract

Abstract Background: Overall survival (OS) of patients with brain metastases treated with hypofractionated (HFSRT) or single-fraction (SRS) radiosurgery depends on several prognostic factors. The aim of this study was to investigate the potential of sex as an independent predictor of OS and evaluate the predictive accuracy of common prognostic scores.Methods: Retrospective analysis of 281 consecutive patients receiving radiosurgery of brain metastases was performed. Kaplan-Meier survival curves and Cox proportional hazards models were used to compare OS between SRS and HFSRT and by sex, before and after propensity-score matching (PSM) on key baseline prognostic covariates. Prognostic scores were evaluated using Harrell’s concordance index.Results: Median OS was 11 months after both SRS and HFSRT. After PSM, median OS was 12 months after SRS (95%CI: 7.5-16.5) and 9 months after HFSRT (95%CI: 5.0-13.0; p=0.77). Independent prognostic factors were sex, primary tumor, KPI, and systemic disease status. Median OS was 16 months for women and 7 months for male patients (p<0.001). After excluding sex specific tumors, PSM revealed a median OS of 16 months for women and 8 months for male patients (p<0.01). Evaluation of prognostic indices showed BSBM to be the most accurate (Harrell’s C=0.68), followed by SIR (0.61), GPA (0.60), RPA (0.58), and Rades et al. (0.57).Conclusions: OS after HFSRT and SRS did not differ, although PSM revealed a non-significant advantage for SRS. Female sex was found to be a major independent positive prognostic factor for survival, and thus should be considered in the personalized decision-making of brain metastases treatment.

Publisher

Research Square Platform LLC

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3